Digoxin effects in infants with single‑ventricle heart failure
Digoxin Pharmacodynamics in Infants with Heart Failure due to Single Ventricle Congenital Heart Disease
This project looks at how the heart drug digoxin behaves and affects newborns and infants who have heart failure from single‑ventricle congenital heart disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-11045660 on NIH RePORTER |
What this research studies
If your baby has single‑ventricle heart disease and heart failure, this work would measure digoxin levels in the blood, check kidney function, and watch how the heart responds while on the medicine. Doctors will collect small blood samples, clinical measurements, and chart information during routine care and use those data to map how dose, growth, and illness change drug exposure and effect. The team will use those measurements to build models that predict safe and effective dosing for different ages and clinical situations. The goal is to reduce guessing about dosing and to help clinicians give the right amount of digoxin to infants with this condition.
Who could benefit from this research
Good fit: Ideal candidates are newborns and infants with single‑ventricle congenital heart disease who have heart failure and who are receiving or may receive digoxin as part of their care.
Not a fit: Children without single‑ventricle heart disease, older children or adults, or patients who will not receive digoxin are unlikely to benefit directly from this work.
Why it matters
Potential benefit: If successful, this could lead to safer, more accurate digoxin dosing and potentially fewer deaths or transplants among infants with single‑ventricle heart failure.
How similar studies have performed: Retrospective studies suggested digoxin may improve survival in infants with single‑ventricle disease, but prospective pharmacokinetic/pharmacodynamic studies in this population are new.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Hornik, Christoph — Duke University
- Study coordinator: Hornik, Christoph
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.